Loading clinical trials...
Loading clinical trials...
Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma
Conditions
Interventions
Ramucirumab
Locations
45
United States
Arizona Clinical Research Center
Tucson, Arizona, United States
USC Norris Cancer Hospital
Los Angeles, California, United States
Carolinas Medical Center
Charlotte, North Carolina, United States
Oklahoma Cancer Specialists & Research Institute, LLC
Tulsa, Oklahoma, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Buenos Aires, Argentina
Start Date
July 7, 2015
Primary Completion Date
November 18, 2016
Completion Date
June 5, 2019
Last Updated
June 29, 2020
NCT06340711
NCT05969860
NCT04895709
NCT04704661
NCT06901531
NCT07462923
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions